Industry

Discover dsm-firmenich’s pioneering longevity science at Vitafoods 2026

Visitors to booth #3C88 in Barcelona this May can explore how dsm-firmenich is unlocking increased health expectancy with the latest science-backed innovations targeting the cellular hallmarks of aging.

EMA opens consultation on non-clinical requirements for microbiome-based medicines: what companies should do now

CHMP has announced the development of a dedicated reflection paper on the non-clinical development and evaluation of microbiome-based medicinal products (MMPs).

Postbiotics: the story, the evidences, the ingredient

How postbiotics are reshaping dietary supplements and pharma: key insights from Humiome® Post LB.

When a microbiome drug steps onto hematology’s main stage

MaaT Pharma, based in Lyon and listed on Euronext Paris, unveiled the final results of its ARES Phase 3 trial of Xervyteg® (MaaT013).

Probiotics and prevention: the €10 billion question for Europe

New IPA Europe analysis puts hard numbers on how evidence-based probiotic use could cut healthcare costs and boost productivity across the EU.

IPA Europe brings probiotic economy to the fore at Brussels policy summit

2 December event in Brussels will unveil new socio-economic analysis on how clearer EU rules for probiotics could cut healthcare costs, drive innovation and strengthen the single market.

The story of three new probiotics: from infancy to discovery

Bifidobacterium breve 2TA, Lacticaseibacillus rhamnosus L13B, and Lactobacillus gasseri L6 are not just bacteria: they are witnesses to the intimate, ancestral dialogue between mothers, infants, and microbes.

SynBalance and SkyrBiotics®: a new alliance for the future of functional dairy

Through this collaboration, the Icelandic tradition of dairy innovation merges with Italian scientific expertise to drive the future of functional nutrition.

Microbiome therapy hits Phase 3 milestone: MaaT Pharma’s Xervyteg delivers in refractory GI-aGvHD ahead of ASH 2025 and EMA review

At the 67th ASH, one of hematology’s biggest stages, the Lyon-based biotech will present pivotal Phase 3 results that can bend treatment paradigms.

Health Canada Authorizes Functional Claims for SynbÆctive® ProBeautyShield

ProBeautyShield by SynBalance is an innovative probiotic complex developed to support and protect skin health.

Subscribe to MicrobiomePost newsletter

Take full advantage of MicrobiomePost‘s features.